GNX203 is GlycoNex's preclinical bispecific antibody-drug conjugate program — a novel bispecific ADC design combining glycan and protein tumor antigen targeting. The dual-recognition design aims to improve tumor selectivity, enhance therapeutic efficacy, and mitigate resistance mechanisms associated with single-target ADC approaches. GNX203 is being developed for difficult-to-treat solid tumors with limited treatment options, with current focus on pancreatic, colorectal, and selected gynecologic cancers. The candidate is in Lead Optimization, having completed drug candidate screening and intellectual property positioning. The glycan-targeting arm is derived from GlycoNex's proprietary GlycoSH antibody library — the same two-decade glycobiology platform that underpins the company's ADC and pro-antibody pipeline programs. Specific target identities will be disclosed in line with patent prosecution progress.
GNX203
A Novel Bispecific ADC Combining Glycan and Protein Tumor Antigen Targeting
Overview
Dual-Recognition Design
Arm A binds tumor glycan
Glycan-targeting arm recognizes a tumor-associated carbohydrate antigen overexpressed on malignant cells.
Arm B binds tumor protein
Protein-targeting arm engages a complementary surface antigen on the same tumor cell.
Dual engagement enables selective ADC delivery
Co-binding improves selectivity over single-target ADCs and triggers internalization for cytotoxic payload release.
Most clinical-stage bispecific ADCs in development today — including programs from SystImmune (BL-B01D1), Zymeworks (ZW251), Merck KGaA (M1231), and AstraZeneca (AZD9592) — combine two protein antigens on the same antibody. GNX203's design departs from this convention by pairing a tumor-associated glycan with a tumor protein antigen, leveraging the orthogonal expression patterns of carbohydrate versus protein markers on epithelial tumors.
The dual-recognition logic addresses two persistent limitations of single-target ADC therapy: tumor heterogeneity (where some malignant cells underexpress the chosen antigen) and acquired antigen-loss resistance. By requiring engagement of two independent antigens, GNX203 is designed to engage a broader fraction of tumor cells and remain effective in the face of single-marker drift.
Targeting Underserved Solid Tumors
Pancreatic Cancer
Pancreatic adenocarcinoma has minimal viable targeted-therapy options after first-line failure. The GNX203 dual-recognition design is being evaluated for its potential to address heterogeneous antigen expression in this hard-to-treat malignancy.
Colorectal Cancer
mCRC patients refractory to chemotherapy and existing targeted regimens face limited options. Bispecific antigen engagement may extend coverage to subpopulations underserved by single-target ADC approaches.
Gynecologic Cancers
Selected gynecologic malignancies — including ovarian and endometrial cancers with limited targeted therapy — represent a focus area where dual-antigen recognition could expand patient eligibility beyond single-marker-defined cohorts.
GNX203's three indication arms are pursued as parallel exploratory programs rather than a single lead. Antibody-driven patient stratification — selecting patients based on dual-antigen expression profiles — will guide which solid tumor types advance to formal clinical evaluation.
Development Status
-
Lead candidate screening & IP positioning
Drug candidate selection and patent application across multiple jurisdictions.
-
Lead optimization in progress
Candidate refinement, in vivo activity validation, and IP prosecution.
-
Next
Preclinical advancement
Toxicology and CMC development upon candidate finalization.
-
Future
Clinical translation
Regulatory engagement and IND-enabling work scheduled in line with preclinical readout. Specific timing is not currently disclosed.
Why GNX203's Design Is Distinct
Glycan + protein combination
Departs from the protein × protein bispecific convention used by every clinical-stage BsADC currently disclosed, exploiting the orthogonality of glycan and protein tumor markers.
Anchored in the GlycoSH library
The glycan-recognition arm is drawn from the GlycoSH antibody library, accumulated since GlycoNex's founding in 2001 in collaboration with the late Dr. Sen-itiroh Hakomori (US National Academy of Sciences).
Addresses single-target resistance
Dual-antigen engagement is designed to remain effective against tumor heterogeneity and antigen-loss escape — common failure modes for single-target ADC programs.
Built for technology partnership
Designed with co-development openness in mind — particularly for partners contributing complementary linker chemistry, payload diversity, or conjugation engineering capability.
References
- Bispecific ADC literature reviews — available on request
- GlycoNex internal preclinical data — confidential; partner inquiries welcomed
- Patent applications — under prosecution across multiple jurisdictions; details disclosed upon publication
- Taiwan TWSE Material Information Disclosure — TWSE 4168
Partner with us on GNX203
GlycoNex is developing GNX203 in-house and is actively open to co-development partnerships with companies bringing complementary ADC technology — particularly in linker chemistry, payload diversity, or conjugation engineering. We contribute antibody discovery (via the GlycoSH platform) and bispecific format design.